Browsing: Lillys

By Bhanvi Satija and Patrick Wingrove (Reuters) -Sales of Eli Lilly (NYSE:)’s high profile weight-loss and diabetes drugs fell short…

Eli Lilly’s highly popular weight loss drug reduced the risk of developing Type 2 diabetes by 94% in obese or…

Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time…

A panel of independent advisors to the Food and Drug Administration on Monday recommended Eli Lilly’s Alzheimer’s drug donanemab, paving…

The market for weight-loss drugs such as Ozempic and Wegovy will keep surging due to new products including Eli Lilly’s…

Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a…